Acosta PL, Caballero MT, Polack FP (2016) Brief history and characterization of enhanced respiratory syncytial virus disease. Clinical and Vaccine Immunology 23(3): 189-195.

Afrough B, Dowall S, Hewson R ( 2019). Emerging viruses and current strategies for vaccine intervention. The Journal of Translational Immunology 196: 157-166.

Al-Kassmy J, Pedersen J, Kobinger G (2020) Vaccine Candidates against Coronavirus Infections. Where Does COVID-19 Stand?. Viruses 12(8):E861.

Amanat F, Krammer F (2020) SARS-CoV-2 vaccines: status report. Immunity 52(4): 583-589.

Arumugam VA, Thangavelu S, Fathah Z, et al. (2020) COVID-19 and the World with Co-Morbidities of Heart Disease, Hypertension and Diabetes. Journal of Pure and Applied Microbiology 14(3):1623-1638. doi: 10.22207/JPAM.14.3.01.

Begum J, Mir NA, Dev K, Buyamayum B, Wani MY, Raza M (2020) Challenges and prospects of COVID-19 vaccine development based on the progress made in SARS and MERS vaccine development. Transboundary and Emerging Diseases https://doi.org/10.1111/tbed.13804.

Bisht H, Roberts A, Vogel L, Bukreyev A, Collins PL, Murphy BR, Subbarao K, Moss B (2004) Severe acute respiratory syndrome coronavirus spike protein expressed by attenuated vaccinia virus protectively immunizes mice. Proceedings of the National Academy of Sciences 101(17): 6641-6646.

Brauer F, Castillo-Chavez C, Castillo-Chavez C (2012) Mathematical models in population biology and epidemiology (Vol. 2). New York: Springer Pp. 508.

Bukreyev A, Lamirande EW, Buchholz UJ, Vogel LN, Elkins WR, St Claire M, Murphy BR, Subbarao K, Collins PL (2004) Mucosal immunisation of African green monkeys (Cercopithecus aethiops) with an attenuated parainfluenza virus expressing the SARS coronavirus spike protein for the prevention of SARS. The Lancet, 363(9427): 2122-2127.

Cai Y, Zhang J, Xiao T, Peng H, Sterling SM, Jr RMW, Rawson S, Rits-Volloch S, Chen B (2020) Distinct conformational states of SARS-CoV-2 spike protein. Science 369 (6511): 1586-1592.

Calina D, Hartung T, Docea AO, et al. (2020) COVID-19 vaccines: ethical framework concerning human challenge studies. Daru 1-6. doi: 10.1007/s40199-020-00371-8.

Callaway E (2020) Fast-track coronavirus vaccine draws outrage over safety. Nature 584(7821):334-335.

Carlson R (2020) CVnCoV SARS-CoV-2 vaccine. Precision vaccination. https://www.precisionvaccinations.com/vaccines/cvncov-sars-cov-2-vaccine.: Accessed on: 29 August 2020.

Conforti A, Marra E, Roscilli G, Palombo F (2020) Are Genetic Vaccines the right weapon against COVID-19. Molecular therapy 28: 1555-1556.

Corbett KS, Flynn B, Foulds KE, Francica JR, Boyoglu-Barnum S, Werner AP, Nagata BM et al  (2020) Evaluation of the mRNA-1273 vaccine against SARS-CoV-2 in nonhuman primates. New England Journal of Medicine 383:1544-1555.

COVID- 19 Vaccine development using new, fast-growing tobacco plant technology., Crop Biotech Update. (2020) ISAAAhttp://www.isaaa.org/kc/cropbiotechupdate/article/default.asp?ID=18081 accessed on 22 April 2020.

Dhama K, Khan S, Tiwari R, Sircar S, Bhat S, Malik YS, Singh KP, Chaicumpa W, Bonilla-Aldana DK, Rodriguez-Morales AJ (2020a) Coronavirus Disease 2019-COVID-19. Clinical Microbiology Reviews 33(4):e00028-20. doi: 10.1128/CMR.00028-20.

Dhama K, Natesan S, Yatoo MI, Patel SK, Tiwari R, Saxena SK, Harapan H (2020d) Plant-based vaccines and antibodies to combat COVID-19: Current status and prospects. Human Vaccines and Immunotherapeutics 16(12):  https://doi.org/10.1080/21645515.2020.1842034. 

Dhama K, Patel SK, Sharun K, Pathak M, Tiwari R, Yatoo MI, Malik YS, Sah R, Rabaan AA, Panwar PK, Singh KP, Michalak I, Chaicumpa W, Martinez-Pulgarin DF, Bonilla-Aldana DK, Rodriguez-Morales AJ (2020b) SARS-CoV-2 jumping the species barrier: Zoonotic lessons from SARS, MERS and recent advances to combat this pandemic virus. Travel Medicine and Infectious Disease 37:101830. doi: 10.1016/j.tmaid.2020.101830.

Dhama K, Sharun K, Tiwari R, Dadar M, Malik YS, Singh KP, Chaicumpa W (2020c) COVID-19, an emerging coronavirus infection: advances and prospects in designing and developing vaccines, immunotherapeutics, and therapeutics. Human Vaccines and Immunotherapeutics 16(12): doi: 10.1080/21645515.2020.1735227.

DiazGranados CA, Dunning AJ, Jordanov E, Landolfi V, Denis M, Talbot HK (2013) High-dose trivalent influenza vaccine compared to standard dose vaccine in elderly adults: safety, immunogenicity and relative efficacy during the 2009-2010 season. Vaccine 31: 861–86610.1016/j.vaccine.2012.12.013

Dror AA, Eisenbach N, Taiber S, et al. (2020) Vaccine hesitancy: the next challenge in the fight against COVID-19 (published online ahead of print, 2020 Aug 12). European Journal of Epidemiology 35(8): 775-779.

Du L, Zhao G, Lin Y, Sui H, ChanC., Ma S, et al. (2008) Intranasal vaccination of recombinant adeno-associated virus encoding receptor-binding domain of severe acute respiratory syndrome coronavirus (SARS-CoV) spike protein induces strong mucosal immune responses and provides long-term protection against SARS-CoV infection. The Journal of Immunology 180(2): 948-956.

ECDC (European Center for disease prevention and control) (2020) Immune response and immunity to SARS-CoV-2. Available at https://www.ecdc.europa.eu/en/covid-19/latest-evidence/immune-responses accessed on: 29 August 2020.

Ertl HCJ (2016) Viral vectors as vaccine carriers. Current Opinion in Virology 17: 1-8.

Francis MJ (2017) Recent advances in vaccine technology. The veterinary clinics of north Ameria, small animal practice 48(2): 231-241.

Frederiksen LSF, Zhang Y, Foged C, Thakur A (2020) The Long Road Toward COVID-19 Herd Immunity: Vaccine Platform Technologies and Mass Immunization Strategies. Frontiers in Immunology 11:1817.

Funk CD, Laferriere C, Ardakani A (2020) A snapshot of the global race for vaccines targeting SARS-CoV-2 and the COVID-19 pandemic. Frontiers in Pharmacology 11(937): 1-17.

Guroff MR (2007) Replication and non-replication viral vectors for vaccine development. Current Opinion in Biotechnology 18: 546-556.

Hartung H, Aktas O (2020) COVID-19 and management of neuroimmunological disorders. Nature Reviews Neurology 16: 347–348. https://doi.org/10.1038/s41582-020-0368-9.

Heath PT, Le Doare K, Khalil A (2020) Inclusion of pregnant women in COVID-19 vaccine development. Lancet Infectious Diseases 20(9):1007-1008.

Hobernik D, Bros M (2018). DNA vaccines—how far from clinical use? International Journal of Molecular Sciences 19(11): 3605.

Infovac (July 24, 2020)  Coronavirus (COVID-19). Available at https://www.infovac.ch/fr:  Accessed on 29 August 2020.

Jackson LA, Anderson EJ, Rouphael NG, et al. (2020) An mRNA Vaccine against SARS-CoV-2 - Preliminary Report. New England Journal of Medicine, 383:1920-1931. DOI: 10.1056/NEJMoa2022483.

Jefferys R (2020) COVID-19 vaccines. Available at  https://www.infovac.ch/fr/Jeffreys Accessed on: 29 August 2020.

Kao CM, Orenstein WA, Anderson EJ (2020) The Importance of Advancing SARS-CoV-2 Vaccines in Children. Clinical Infectious Diseases 712: 1-4.

Kaur SP, Gupta V (2020) COVID-19 Vaccine: A comprehensive status report. Virus Research 288: 198114.

Khan T (2020) Genexine consortium develops COVID-19 vaccine for human testing. Available at https://pharmashots.com/press-releases/korean-biotech-firm-genexines-covid-19-deoxyribonucleic-acid-vaccine-pipeline-gx-19-is-ready-for-clinical-testing-as-soon-as-it-applies-to-the-drug-ministry-for-human-testing/ access on 25^th October 2020.

Khuroo MS, Khuroo M, Khuroo MS, Sofi AA, Khuroo NS (2020) COVID-19 Vaccines: A Race Against Time in the Middle of Death and Devastation! Journal of Clinical and Experimental Hepatology https://doi.org/10.1016/j.jceh.2020.06.003.

King A (2020) Explainer: how is the vaccine pipeline for Covid-19 looking? 30 June 2020.; Chemistry world, Available at https://www.chemistryworld.com/news/explainer-how-is-the-vaccine-pipeline-for-covid-19 looking/4012068.article accessed on: 29 August 2020.

Koirala A, Joo YJ, Khatami A, Chiu C, Britton N (2020) Vaccines for COVID-19: the current state of play. Paediatric Respiratory Reviews 35: 43-49.

Krause P, Fleming TR, Longini I, Henao-Restrepo AM, Peto R (2020) World Health Organization Solidarity Vaccines Trial Expert Group. COVID-19 vaccine trials should seek worthwhile efficacy. Lancet 396(10253): 741-743.

Lan J, Ge J, Yu J, Shan S, Zhou H, Fan S, Zhnag Q, Shi X, Wang Q, Zhang L, Wang X (2020) Structure of the SARS-CoV-2 spike receptor-binding domain bound to the ACE2 receptor. Nature 581(7807): 215-220.

Lauxmann MA, Santucci NE, Autran-Gomez AM (2020) The SARS-CoV-2 Coronavirus and the COVID-19 Outbreak. International Brazilian Journal of Urology 46(1): 6-18.

Liu W, Tao ZW, Wang L, Yuan ML, Liu K, Zhou L, et al. (2020) Analysis of factors associated with disease outcomes in hospitalized patients with 2019 novel coronavirus disease. Chinese Medical Journal 133(9): 1032–1038.

Manam S, Ledwith BJ, Barnum AB, Troilo PJ, Pauley CJ, Harper LB, Pacchione SJ, et al. (2000) Plasmid DNA vaccines: tissue distribution and effects of DNA sequence, adjuvants and delivery method on integration into host DNA. Intervirology 43(4-6): 273-281.

Marasini N, Kaminskas LM (2019) Subunit-based mucosal vaccine delivery systems for pulmonary delivery-Are they feasible? Drug Development and Industrial Pharmacy 45(6): 882-894.

Markusic DM, Nichols TC, Merricks EP, et al. (2017) Evaluation of engineered AAV capsids for hepatic factor IX gene transfer in murine and canine models. Journal of Translational Medicine  15: 94. https://doi.org/10.1186/s12967-017-1200-1Markusic& Herzog 2016.

Michelozzi P, de’Donato F, Scortichini M, De Sario M, Noccioli F, Rossi P, Davoli M (2020) Mortality impacts of the coronavirus disease (COVID-19) outbreak by sex and age: rapid mortality surveillance system, Italy, 1 February to 18 April 2020. Eurosurveillance 25(19): 2000620.

Ming WK, Huang J, Zhang CJ (2020) Breaking down of healthcare system: Mathematical modelling for controlling the novel coronavirus (2019-nCoV) outbreak in Wuhan, China. bioRxiv, doi: https://doi.org/10.1101/2020.01.27.922443.

Murugan, (2020) How Indigenous is Bharat Biotech’s New COVID-19 Vaccine, Covaxin? Available at https://science.thewire.in/health/how-indigenous-is-bharat-biotechs-new-covid-19-vaccine-covaxin; accessed on 29 August 2020.

Nesteruk I (2020) Statistics-based predictions of coronavirus epidemic spreading in mainland China. Innovative Biosystems and Bioengineering 4(1): 13–18.

Oduwole HK, Kimbir AR (2018) Modelling vertical transmission and the effect of Antiretroviral Therapy (ART) on the dynamics of HIV/AIDS in an age-structured population in Nigeria. Journal of Natural and Applied Sciences -Nasara Scientifique 7 (1): 51-78.

Peeples L (2020) News Feature: Avoiding pitfalls in the pursuit of a COVID-19 vaccine. Proceedings of the National Academy of Sciences 117(15): 8218-8221.

Rabaan AA, Al-Ahmed SH, Sah R, Al-Tawfiq JA, Al-Qaaneh AM, Al-Jamea LH, Woodman A, Al-Qahtani M, Haque S, Harapan H, Bonilla-Aldana DK, Kumar P, Dhama K, Rodriguez-Morales AJ (2020b) Recent advances in vaccine and immunotherapy for COVID-19. Human Vaccines and Immunotherapeutics 16(12): doi: 10.1080/21645515.2020.1825896.

Rabaan AA, Al-Ahmed SH, Sah R, Tiwari R, Yatoo MI, Patel SK, Pathak M, Malik YS, Dhama K, Singh KP, Bonilla-Aldana DK, Haque S, Martinez-Pulgarin DF, Rodriguez-Morales AJ, Leblebicioglu H (2020a) SARS-CoV-2/COVID-19 and advances in developing potential therapeutics and vaccines to counter this emerging pandemic. Annals of Clinical Microbiology and Antimicrobials 19(1):40. doi: 10.1186/s12941-020-00384-w.

Rauch S, Jasny E, Schmidt KE, Petsch B (2018) New vaccine technologies to combat outbreak situations. Frontiers in Immunology 9: 1963.

Rego GN, Nucci MP, Alves AH, Oliveira FA, Marti LC, Nucci LP, Mamani JB, Gamarra LF (2020) Current Clinical Trials Protocols and the Global Effort for Immunization against SARS-CoV-2. Vaccines 8(3): 474.

Riedel S (2005) Edward Jenner and the history of smallpox and vaccination. Baylor University Medical Center Proceedings Taylor & Francis 18 (1): 21-25.

Rodriguez-Morales AJ, Bonilla-Aldana DK, Tiwari R, Sah R, Rabaan AA, Dhama K (2020) COVID-19, an emerging coronavirus infection: current scenario and recent developments – an overview.  Journal of Pure and Applied Microbiology 14(1): 05-12. https://doi.org/10.22207/JPAM.14.1.02

Salvatori G, Luberto L, Maffei M, Aurisicchio L, Roscilli G, Palombo F, Marra E (2020) SARS-CoV-2 SPIKE PROTEIN: an optimal immunological target for vaccines. Journal of Translational Medicine 18: 1-3.

Sambhara S, McElhaney JE (2009) Immunosenescence and Influenza Vaccine Efficacy. In: Compans R, Orenstein W (Eds.) Vaccines for Pandemic Influenza. Current Topics in Microbiology and Immunology, Vol 333. Springer, Berlin, Heidelberg.

Shang J, wan Y, Luo C, Ye G, Geng Q, Auerbach A, Li F (2020) Cell entry mechanisms of SARS-CoV-2. PNAS 117(21): 11727-11734.

Shi R, Shan C, Duan X, Chen Z, Liu P, et al. (2020a) A human neutralizing antibody targets the receptor binding site of SARS-CoV-2. Nature 584: 120-124.

Shi Y, Wang G, Cai XP, Deng JW, Zheng L, Zhu HH, Zheng M, Yang B, Chen Z (2020b) An overview of COVID-19. Journal of Zhejiang University-SCIENCE B (Biomedicine & Biotechnology) 21(5): 343-360.

Shin MD, Shukla S, Chung YH,  et al. (2020) COVID-19 vaccine development and a potential nanomaterial path forward. Nature Nanotechnology 15: 646–655. https://doi.org/10.1038/s41565-020-0737-y.

Smith MJ, Hayward SA, Innes SM, Miller ASC (2020) Point?of?care lung ultrasound in patients with COVID?19–a narrative review. Anaesthesia 75 (8): 1096-1104.

Song, W, Gui M, Wang X, Xiang Ye (2020) Cryo-EM structure of the SARS coronavirus spike glycoprotein in complex with its host cell receptor ACE2. PLoS Pathology 14(8): 1-19.

Strugnell R, Zepp F, Cunningham A, Tantawichien T (2011) Vaccine antigens. Perspect Vaccinol 1(1): 61-88.

Tai W, He L, Zhang X, Pu J, Voronin D, Jiang S, Zhou Y, Du L (2020) Characterization of the receptor-binding domain (RBD) of 2019 novel coronavirus: implication for development of RBD protein as a viral attachment inhibitor and vaccine. Cellular & Molecular Immunology 17(6): 613-620.

Tiwari R, Dhama K, Sharun K, Iqbal Yatoo M, Malik YS, Singh R, Michalak I, Sah R, Bonilla-Aldana DK, Rodriguez-Morales AJ
(2020) COVID-19: animals, veterinary and zoonotic links. Veterinary Quarterly 40(1):169-182. doi: 10.1080/01652176.2020.1766725.

Urakami A, Sakurai A, Ishikawa M, Yap ML, Flores-Garcia Y, Haseda Y, Aoshi T, Zavala FP, Rossmann MG, Kuno S, Ueno R, Akahata W (2017) Development of a novel virus-like particle vaccine platform that mimics the immature form of alphavirus. Clinical and Caccine Immunology 24(7): 1-14.

Vetter V, Denizer G, Friedland LR, Krishnan J, Shapiro M (2018) Understanding modern-day vaccines: what you need to know. Annals of medicine 50(2): 110-120.

Wallis J, Shenton DP, Carlisle RC (2019) Novel approaches for the design, delivery and administration of vaccine technologies. Clinical & Experimental Immunology 196(2): 189-204.

Walls AC, Park YJ, Tortorici MA, Wall A, McGuir AT, Veesler D (2020). Structure, Function, and Antigenicity of the SARS-CoV-2 Spike Glycoprotein. Cell 181(2): 281-292.

Wang J, Peng Y, Xu H, Cui Z, Williams RO (2020) The COVID-19 vaccine race: Challenges and opportunities in vaccine formulation. AAPS pharmSciTech 21 (6): 225.

Wolff JA, Ludtke JJ, Acsadi G, Williams P, Jani A (1992) Long-term persistence of plasmid DNA and foreign gone expression in mouse muscle. Human Molecular Genetics 1(6): 363-369.

Wu L, Wang N, Chang Y, Tian X, Na D, Zhang L, Zheng L, Nan T, Wang L & Liang G (2007) Duration of antibody responses after severe acute respiratory syndrome. Emerging Infectious Diseases 13(10): 1562–1564.

Yatoo MI, Hamid Z, Parray OR, Wani AH, Ul Haq A, Saxena A, Patel SK, Pathak M, Tiwari R, Malik YS, Sah R, Rabaan AA, Rodriguez Morales AJ, Dhama K. (2020) COVID-19 - Recent advancements in identifying novel vaccine candidates and current status of upcoming SARS-CoV-2 vaccines. Human Vaccines and Immunotherapeutics 1-14. doi: 10.1080/21645515.2020.1788310.

Zhu G, Zhu C, Zhu Y, Sun F (2020). Minireview of progress in the structural study of SARS-CoV-2 proteins. Current Research in Microbial Sciences 1: 53-61.